Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - GI - NCCTG-N014A
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary - Preliminary - GI - NCCTG-N044J
Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - NCCTG-N0147
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - GI - NCCTG-N9945
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary - Preliminary - GI - N0849
Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary - Primary - GI - N044J
Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary - Primary - GI - N0041
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66 Alberts, Steven R. , Roh, Mark S. , Mahoney, Michelle R. ... - - J Clin Oncol - 2010 Manuscript - Primary - Primary - GI - N9945
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary - Primary - GI - N0147
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. Alberts, Steven R , Sande, Jonathan R , Foster, Nathan R ... - - J Gastrointest Cancer - 2007 Manuscript - Primary - Primary - GI - NCCTG-N9943
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007 Manuscript - Primary - Primary - GI - NCCTG-964251
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007 Manuscript - Primary - Long-Term-Followup - GI - NCCTG-9741
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators Bardia, A. , Loprinzi, C. , Grothey, A. , Nelson, G. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0148
Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators Bardia, Aditya , Loprinzi, Charles , Grothey, Axel , Nelson, Garth ... - - Semin Oncol - 2010 Manuscript - Secondary-not-in-original - Primary - GI - N0148
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52 Bolton, J. S. , O'Connell, M. J. , Mahoney, M. R. , Farr, G. H. Jr ... - - Clin Colorectal Cancer - 2012 Manuscript - Primary - Primary - GI - NCCTG-924652
Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance) Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016 Abstract - Primary - Preliminary - Experimental - N1153
Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Cheung, W. Y. , Shi, Q. , O'Connell, M. , Cassidy, J. , Blanke, C. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - NCCTG-N0441
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database Cheung, Winson Y. , Shi, Qian , O’Connell, Michael , Cassidy, James ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary - Primary - GI - N0441
Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144 Dy, Grace K. , Hobday, Timothy J. , Nelson, Garth ... - - Clin Colorectal Cancer - 2009 Manuscript - Primary - Primary - GI - N0144
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. Dy, Grace K , Krook, James E , Green, Erin M , Sargent, Daniel J ... - - J. Clin. Oncol. - 2007 Manuscript - Secondary - Primary - GI - N9741
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTGs phase III trials N9741 and N9841. Franko, J. , Shi, Q. , Goldman, C. D. , Pockaj, B. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 Franko, Jan , Shi, Qian , Goldman, Charles D. , Pockaj, Barbara A. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101 Fuchs, C. S. , Tepper, J. E. , Niedzwiecki, D. , Hollis, D. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - GI - CALGB-80101
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance) Fuchs, Charles S. , Niedzwiecki, Donna , Mamon, Harvey J. ... - - J. Clin. Oncol - 2017 Manuscript - Primary - Primary - GI - CALGB-80101
Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). Gill, S. , Loprinzi, C. , Kennecke, H. , Grothey, A. , Nelson, G. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Comprehensive - GI - N0148
Prognostic Web-based Models for Stage II and III Colon Cancer: a Population and Clinical Trials-based Validation of Numeracy and Adjuvant! Online Gill, Sharlene , Loprinzi, Charles , Kennecke, Hagen , Grothey, Axel ... - - Cancer - 2011 Manuscript - Secondary-not-in-original - Meta-Analysis - GI - NCCTG-89-46-51 , NCCTG-914653
Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Goldberg, R. , Sargent, D. , Thibodeau, S. , Mahoney, M. , Shields, A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - N0147
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Goldberg, Richard M , Sargent, Daniel J , Morton, Roscoe F ... - - J. Clin. Oncol. - 2004 Manuscript - Primary - Primary - GI - NCCTG-N9741
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147 Gonsalves, Wilson I. , Mahoney, Michelle R. , Sargent, Daniel J. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group Study N054C Grothey, A. , Lafky, J. M. , Morlan, B. W. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - GI - N054C
Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 Grothey, Axel , Nikcevich, Daniel A. , Sloan, Jeff A. ... - - J Clin Oncol - 2011 Manuscript - Primary - Primary - Symptom Inter - N04C7
Phase II study of oxaliplatin, 5-FU and RT followed by gemcitabine in patients with unresectable pancreatic cancer. Haddock, M. , Kim, G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary - Primary - GI - NCCTG-N0349
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. Haddock, Michael G , Swaminathan, Revathi , Foster, Nathan R ... - - J. Clin. Oncol. - 2007 Manuscript - Primary - Primary - GI - N9942
A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance) Halfdanarson, Thorvardur R. , Foster, Nathan R. , Kim, George P. ... - - Oncologist - 2019 Manuscript - Primary - Primary - GI - N064B
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC Hines, Stephanie L. , Mincey, Betty , Dentchev, Todor ... - - Breast Cancer Res. Treat. - 2009 Manuscript - Primary - Primary - Symptom Inter - N03CC
Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147 Huang, J. , Sargent, D. J. , Mahoney, M. R. , Shields, A. F. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - GI - N0147
Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147 Huang, Jocelin , Nair, Suresh G. , Mahoney, Michelle R. ... - - Clin Colorectal Cancer - 2014 Manuscript - Primary - Long-Term-Followup - GI - NCCTG-N0147
Phase I evaluation of sorafenib (SOR) & bevacizumab (BEV) in first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group Trial N0745 Hubbard, J. , Alberts, S. , Loui, W. , Mahoney, M. , Roberts, L. ... - - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - GI - N0745
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance) Hubbard, Joleen M. , Mahoney, Michelle R. , Loui, William S. ... - - Target Oncol - 2017 Manuscript - Primary - Primary - GI - N0745
Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance) Jansson-Knodell, Claire L. , Foster, Nathan R. , Sargent, Daniel J. ... - - J Gastrointest Oncol - 2017 Manuscript - Secondary-not-in-original - Primary - Prevention - N0147
Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials Jatoi, A. , Foster, N. R. , Egner, J. , Burch, P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - GI - N064C
Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)1 Jatoi, Aminah , Dakhil, Shaker R. , Foster, Nathan R. , Ma, Cynthia ... - - J Thorac Oncol - 2008 Manuscript - Primary - Primary - GI - N044B
Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials Jatoi, Aminah , Foster, Nathan R. , Egner, James R. ... - - Int. J. Oncol. - 2010 Manuscript - Primary - Primary - Experimental - N064C
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147 Jatoi, Aminah , Green, Erin M. , Rowland, Jr. Kendrith M. ... - - Oncology - 2009 Manuscript - Secondary - Primary - GI - N0147
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Jatoi, Aminah , Martenson, James A , Foster, Nathan R ... - - Am. J. Clin. Oncol. - 2007 Manuscript - Primary - Primary - GI - N0044
Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal Junction Tumors Jatoi, Aminah , Soori, Gamini , Foster, Nathan R. , Hiatt, Bradley ... - - J Thorac Oncol - 2010 Manuscript - Primary - Primary - GI - N044E
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E Katipamula, Rajini , Jatoi, Aminah , Foster, Nathan R. ... - - Clin Med Oncol - 2008 Manuscript - Secondary - Preliminary - GI - N044E
Borderline resectable pancreatic cancer: Need for Standardization and Methods for Optimal Clinical Trial Design Katz, Matthew HG , Marsh, Robert , Herman, Joseph M. , Shi, Qian ... - - Ann. Surg. Oncol. - 2013 Manuscript - No-Endpoint - Comprehensive - GI - A021101
North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer Kim, G. P. , Foster, N. R. , Haddock, M. G. , Dakhil, S. R. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - GI - N064A
Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma Kim, G. P. , Foster, N. R. , Salim, M. , Flynn, P. J. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - GI - N064B
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary - Long-Term-Followup - GI - NCCTG-N0349
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemicitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. , Foster, N. R. , Bollinger, J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary - Long-Term-Followup - GI - N0349
Phase II of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma Kim, G. P. , Oberg, A. L. , Foster, N. R. , Jaslowski, A. ... - ASCO - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - GI - N034A
Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841 Kim, George P. , Sargent, Daniel J. , Mahoney, Michelle R. ... - - J Clin Oncol - 2009 Manuscript - Primary - Primary - GI - N9841
Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib Lafky, J. M. , Anderson, S. K. , Morlan, B. W. , Nelson, G. D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary-not-in-original - Primary - GI - N054C
Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BEV) and sorafenib Lafky, J. M. , Bot, B. M. , Morlan, B. W. , Anderson, S. K. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - GI - N054C
Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147 Lee, A. , Shi, Q. , Pavey, E. , Sargent, D. J. , Alberts, S. R. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - - Pharmacogenet. Genomics - 2016 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147) Lee, Adam M. , Shi, Qian , Pavey, Emily , Alberts, Steven R. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). Lee, H , Sha, D , Foster, N R , Shi, Q , Alberts, S R , Smyrk, T C ... - - Ann. Oncol. - 2020 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association of micropapillary architecture and high tumor budding with prognosis in patients with stage III colon cancer from a FOLFOX-based adjuvant chemotherapy trial: NCCTG N0147 (Alliance) Lee, Hee Eun , Shi, Qian , Foster, Nate , Chan, Emily , Gill, Sharlene ... - USCAP - Mod Pathol - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Quality of life (QOL) for patients treated with FOLFOX+/-cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147 Mahoney, M. R. , Sloan, J. A. , Hubbard, J. M. , Liu, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original - Primary - GI - N0147
NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: phase II results Mcwilliams, R. R. , Foster, N. R. , Quevedo, F. J. , Marschke, R. F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - GI - N9943
Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial Mcwilliams, R. R. , Mahoney, M. R. , Marchello, B. T. , Jatoi, A. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - GI - N0543
A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. Mcwilliams, R. R. , Mahoney, M. R. , Sargent, D. J. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer Miyoshi, Jinsei , Toden, Shusuke , Yoshida, Kazuhiro , Toiyama, Yuji ... - - Sci Rep - 2017 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Genetic correlates of therapeutic toxicities of stage III colon cancer (CC) patients treated with adjuvant FOLFOX+/-cetuximab (Alliance NCCTG N0147) Newcomb, Polly A. , Sun, Wei , Hua, Xinwei , Banbury, Barbara ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary - Primary - PPP - NCCTG-N0147
Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581 Niedzwiecki, Donna , Bertagnolli, Monica M. , Warren, Robert S. ... - - J Clin Oncol - 2011 Manuscript - Primary - Primary - GI - C9581
Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer. Penney, Kathryn L , Banbury, Barbara L , Bien, Stephanie ... - - Clin. Gastroenterol. Hepatol. - 2019 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Genome-wide association with survival in stage II-III colon cancer (CC) clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology) Penney, Kathryn , Banbury, Barbara L. , Shi, Qian ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - PPP - N0147
Smoking status and prognosis in patients with stage III colon cancer: A correlative analysis of NCCTG phase III trial N0147 Phipps, A. I. , Shi, Q. , Limburg, P. L. J. , Nelson, G. D. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary - Primary - GI - N0147
Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147 Phipps, A. I. , Shi, Q. , Newcomb, P. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary - Primary - GI - N0147
Pre-diagnostic physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance) Phipps, Amanda I. , Shi, Qian , Chan, Emily , Gill, Sharlene ... - ASPO - - 2017 Abstract - Secondary - Primary - GI - NCCTG-N0147
Alcohol consumption and prognosis in patients with stage III colon cancer: a correlative analysis of NCCTG phase III trial N0147 Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - GI - N0147
Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147 Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - - Int. J. Cancer - 2016 Manuscript - Secondary - Primary - GI - N0147
Physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance) Phipps, Amanda I. , Shi, Qian , Zemla, Tyler J. , Dotan, Efrat ... - - Cancer Epidemiol. Biomarkers Prev. - 2018 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Activated EGFR as a prognostic marker in human colon cancer Rego, R. L. , Smyrk, T. C. , Foster, N. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original - Primary - GI - N0442
Association study of the let-7 miRNA-complementary site variant in the 3’ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 clinical trial) Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association study of the let-7 microrna-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147 Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan R. , Grothey, Axel ... - - Oncologist - 2016 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Relationship between Metformin use and Recurrence and Survival in Patients (pts) with Resected Stage III Colon Cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - GI - N0147
Prognostic impact of body-mass index upon cancer recurrence and survival in stage III colon cancer patients treated in adjuvant therapy trials Sinicrope, F. , Foster, N. R. , Sargent, D. J. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Primary - Primary - GI - NCCTG-N994C
Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetusimab: NCCTG N0147. Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - - J. Clin. Oncol - 2013 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-89803 , N0147
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance) Sinicrope, Frank A. , Mahoney, Michelle R. , Yoon, Harry H. ... - - Clin. Cancer Res. - 2015 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen J. ... - - JAMA Oncol - 2017 Manuscript - Secondary-not-in-original - Comprehensive - Correl Sci NOS - NCCTG-N0147
Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen Joseph ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ESMO GI - Annals of Oncology - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ASCO GI - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association of an immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX (Alliance N0147) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne , Heying, Erica ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant therapy trial: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Shi, Qian , Lee, Hee Eun , Foster, Nathan R. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy (NCCTG N0147) (Alliance) Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - - Gastroenterology - 2015 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)]. Sinicrope, Frank A. , Shi, Qian , Thibodeau, Stephen N. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Smyrk, Thomas C. , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147
Mutation-Specific Antibody Detects Mutant BRAFV600E Protein Expression in Human Colon Carcinomas Sinicrope, Frank A. , Smyrk, Thomas C. , Tougeron, David ... - - Cancer - 2013 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147. Sinicrope, Frank A. , Yoon, Harry H. , Mahoney, Michelle R. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer Sinicrope, Frank A , Shi, Qian , Hermitte, Fabienne , Zemla, Tyler J ... - - JNCI Cancer Spectr - 2020 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Was it worth it (WIWI)? patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) Phase III Trial N0147 Sloan, J. A. , Mahoney, M. R. , Sargent, D. J. , Hubbard, J. M. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - Health Outcome - NCCTG-N0147
Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). Sloan, J. A. , Shi, Q. , Lee, A. , Diasio, R. B. , Pavey, E. S. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - Health Outcome - NCCTG-N0147
Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody Smyrk, T. C. , Tougeron, D. , Thibodeau, S. N. , Singh, S. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance) Song, Mingyang , Ou, Fang-Shu , Zemla, Tyler J. , Hull, Mark A. ... - - Int. J. Cancer - 2019 Manuscript - Secondary-not-in-original - Primary - GI - N0147
Postdiagnosis marine omega-3 fatty acid intake and survival of stage III colon cancer in North Central Cancer Treatment Group phase III trial N0147 (Alliance) Song, Mingyang , Ou, Fang-Shu , Zemla, Tyler J. , Shi, Qian ... - DDW - Gastroenterology - 2018 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Current Utilization and Surgical Efficacy of Laparoscopic Colectomy in Colon Cancer Sticca, Robert P , Alberts, Steven R , Mahoney, Michelle R ... - - J. Am. Coll. Surg. - 2013 Manuscript - Secondary-not-in-original - Primary - GI - N0147
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer Taieb, Julien , Le Malicot, Karine , Shi, Qian ... - - J. Natl. Cancer Inst - 2016 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials Taieb, Julien , Malicot, Karine Le ... - ASCO - J Clin Oncol - 2015 Abstract - Secondary-not-in-original - Comprehensive - Correl Sci NOS - N0147
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results Venook, A. , Niedzwiecki, D. , Hollis, D. , Sutherland, S. ... - ASCO - J. Clin. Oncol. - 2006 Abstract - Primary - Preliminary - GI - CALGB-80203
Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) Wilcox, Ryan E. , Shi, Qian , Sinicrope, Frank A. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Deletions in HSP110 T17 and Patient Prognosis in Stage III Microsatellite Instable (MSI) Colon Cancers: Findings from CALGB 89803 and NCCTG N0147. Wu, Christina , Shi, Qian , Tomsic, Jerneja , Meyers, Jeffrey ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-89803 , NCCTG-N0147
Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance) Xie, Hao , Lafky, Jacqueline M. , Morlan, Bruce W. ... - - Ther Adv Med Oncol - 2020 Manuscript - Primary - Primary - GI - N054C
Prognostic impact of specific KRAS mutations in codon 12 and 13 in 2,165 BRAF-wildtype colon cancers: Results from NCCTG N0147 (Alliance) Yoon, H. H. , Tougeron, D. , Mahoney, M. R. , Shi, Q. , Sargent, D. J. ... - - European Journal of Cancer - 2013 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]). Yoon, Harry H. , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - GI - N0147
Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients Yoon, Harry H. , Shi, Qian , Alberts, Steven R. ... - - J. Natl. Cancer Inst - 2015 Manuscript - Secondary-not-in-original - Primary - GI - N0147
Inter-tumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch repair-deficient colon cancers: implications for prognosis Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - - Clin. Cancer Res. - 2019 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance) Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance) Yoon, Harry H. , Tougeron, David , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - - JAMA Oncol - 2018 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX + cetuximab in the PETACC8 and N0147 adjuvant trials. Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set de Gramont, Aimery , Hubbard, Joleen , Shi, Qian ... - - J Clin Oncol - 2010 Manuscript - Secondary - Primary - GI - N9741
